Detecting visually significant cataract using retinal photograph-based deep learning
- PMID: 37118370
- PMCID: PMC10154193
- DOI: 10.1038/s43587-022-00171-6
Detecting visually significant cataract using retinal photograph-based deep learning
Erratum in
-
Author Correction: Detecting visually significant cataract using retinal photograph-based deep learning.Nat Aging. 2022 Jun;2(6):562. doi: 10.1038/s43587-022-00245-5. Nat Aging. 2022. PMID: 37118457 Free PMC article. No abstract available.
Abstract
Age-related cataracts are the leading cause of visual impairment among older adults. Many significant cases remain undiagnosed or neglected in communities, due to limited availability or accessibility to cataract screening. In the present study, we report the development and validation of a retinal photograph-based, deep-learning algorithm for automated detection of visually significant cataracts, using more than 25,000 images from population-based studies. In the internal test set, the area under the receiver operating characteristic curve (AUROC) was 96.6%. External testing performed across three studies showed AUROCs of 91.6-96.5%. In a separate test set of 186 eyes, we further compared the algorithm's performance with 4 ophthalmologists' evaluations. The algorithm performed comparably, if not being slightly more superior (sensitivity of 93.3% versus 51.7-96.6% by ophthalmologists and specificity of 99.0% versus 90.7-97.9% by ophthalmologists). Our findings show the potential of a retinal photograph-based screening tool for visually significant cataracts among older adults, providing more appropriate referrals to tertiary eye centers.
© 2022. The Author(s).
Conflict of interest statement
T.H.R. was a scientific advisor to a start-up company called Medi Whale; he received stock as a part of the standard compensation package. T.H.R. also reports personal fees from Allergan and Novartis, and patents pending for: cardiovascular disease diagnosis assistant method and apparatus (10–2018–0166720(KR), 10–2018–0166721(KR), 10–2018–0166722(KR) and PCT/KR2018/016388); diagnosis assistance system (10–2018–0157559(KR), 10–2018–0157560(KR) and 10–2018–0157561(KR)); diagnosis technology using AI (62/694,901 (USA) and 62/776,345 (USA)); method for controlling a portable fundus camera and diagnosing disease using the portable fundus camera (62/715,729 (USA)); and method for predicting cardio-cerebrovascular disease using eye image (10–2017–0175865 (K.R.)). T.Y.W. is a consultant and a member of the advisory boards for Allergan, Bayer, Boehringer Ingelheim, Genentech, Merck, Novartis, Oxurion (formerly ThromboGenics), Roche and Samsung Bioepis, and cofounder of the start-up companies Plano Pte and EyRiS. T.Y.W. also has a patent issued for Deep Learning System for Retinal Diseases (PCT/SG2018/050363, Singapore and 10201901218S (provisional) Singapore). All the other authors declare no competing interests.
Figures



References
-
- Adelson, J. D. et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Global Health10.1016/S2214-109X(20)30489-7 (2020). - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical